Related Experiment Video
Updated: Jul 2, 2025

05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
5.6K
Efficacy of TIPS plus extrahepatic collateral embolisation in real-world data: a validation study.
Lianhui Zhao1,2, Jun Tie3, Guangchuan Wang1,2,4
1Gastroenterology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong Province, People's Republic of China.
BMJ Open Gastroenterology
|February 23, 2024
Summary
Transjugular intrahepatic portosystemic shunt plus extrahepatic collateral embolisation (TIPS+E) significantly reduces rebleeding and hepatic encephalopathy (HE) in cirrhosis patients. Real-world data confirms TIPS+E
Area of Science:
- Hepatology
- Interventional Radiology
- Gastroenterology
Background:
- Transjugular intrahepatic portosystemic shunt (TIPS) is a key treatment for portal hypertension complications.
- Extrahepatic collateral embolisation (TIPS+E) may improve outcomes post-TIPS, but requires real-world validation.
Approach:
- A multicentre retrospective cohort study analyzed 2077 patients with cirrhosis undergoing TIPS±E.
- Propensity score matching (PSM) was used to compare outcomes between TIPS and TIPS+E groups.
- Prognostic models were developed using baseline data, and clinical outcomes were analyzed post-PSM.
Key Points:
- TIPS+E significantly reduced rebleeding, hepatic encephalopathy (HE), and further decompensation (FDC) compared to TIPS alone.
- Specific subgroups, including those using 8 mm stents and embolizing gastric varices with spontaneous portosystemic shunts (GV+SPSS), showed improved outcomes with TIPS+E.
- Optimal control of post-TIPS portal pressure gradient (pPPG) between 7-8.5 mm Hg enhanced prognosis, particularly in the TIPS+E group.
Conclusions:
- Real-world data validates the high efficacy of TIPS+E in reducing rebleeding and HE.
- TIPS+E is particularly beneficial when using 8 mm stents, embolizing GV+SPSS, and maintaining an optimal pPPG.
- These findings support TIPS+E as an effective strategy for managing complications of portal hypertension.
